Question 1

Am I eligible for this trial based on my health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients clinical trial (NCT06119217). Contact the study team or your healthcare provider for specific answers.

Question 2

How does TTX-030 compare to the standard chemotherapy I might receive?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients clinical trial (NCT06119217). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of the treatments in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients clinical trial (NCT06119217). Contact the study team or your healthcare provider for specific answers.

Question 4

How often would I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients clinical trial (NCT06119217). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients clinical trial (NCT06119217). Contact the study team or your healthcare provider for specific answers.

Question 6

How will participation in this trial affect my overall treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients clinical trial (NCT06119217). Contact the study team or your healthcare provider for specific answers.

What this study is about